Skip to main content
eScholarship
Open Access Publications from the University of California

UCSF

UC San Francisco Previously Published Works bannerUCSF

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.

  • Author(s): Deng, Xianding;
  • Garcia-Knight, Miguel A;
  • Khalid, Mir M;
  • Servellita, Venice;
  • Wang, Candace;
  • Morris, Mary Kate;
  • Sotomayor-González, Alicia;
  • Glasner, Dustin R;
  • Reyes, Kevin R;
  • Gliwa, Amelia S;
  • Reddy, Nikitha P;
  • Sanchez San Martin, Claudia;
  • Federman, Scot;
  • Cheng, Jing;
  • Balcerek, Joanna;
  • Taylor, Jordan;
  • Streithorst, Jessica A;
  • Miller, Steve;
  • Sreekumar, Bharath;
  • Chen, Pei-Yi;
  • Schulze-Gahmen, Ursula;
  • Taha, Taha Y;
  • Hayashi, Jennifer M;
  • Simoneau, Camille R;
  • Kumar, G Renuka;
  • McMahon, Sarah;
  • Lidsky, Peter V;
  • Xiao, Yinghong;
  • Hemarajata, Peera;
  • Green, Nicole M;
  • Espinosa, Alex;
  • Kath, Chantha;
  • Haw, Monica;
  • Bell, John;
  • Hacker, Jill K;
  • Hanson, Carl;
  • Wadford, Debra A;
  • Anaya, Carlos;
  • Ferguson, Donna;
  • Frankino, Phillip A;
  • Shivram, Haridha;
  • Lareau, Liana F;
  • Wyman, Stacia K;
  • Ott, Melanie;
  • Andino, Raul;
  • Chiu, Charles Y
  • et al.
Abstract

We identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States. Named B.1.427/B.1.429 to denote its two lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced cases from September 2020 to January 2021, showing 18.6%-24% increased transmissibility relative to wild-type circulating strains. The variant carries three mutations in the spike protein, including an L452R substitution. We found 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation common to variants B.1.1.7, B.1.351, and P.1. Antibody neutralization assays revealed 4.0- to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California exhibiting decreased antibody neutralization warrants further investigation.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View